Departments of Neurosciences and Psychiatry, University of California, San Diego, La Jolla, California.
Department of Medicine, University of California, San Diego, La Jolla, California.
Ann Clin Transl Neurol. 2020 Jul;7(7):1166-1173. doi: 10.1002/acn3.51097. Epub 2020 Jul 3.
Distal sensory polyneuropathy (DSP) and neuropathic pain are important clinical concerns in virally suppressed people with HIV. We determined how these conditions evolved, what factors influenced their evolution, and their clinical impact.
Ambulatory, community-dwelling HIV seropositive individuals were recruited at six research centers. Clinical evaluations at baseline and 12 years later determined neuropathy signs and distal neuropathic pain (DNP). Additional assessments measured activities of daily living and quality of life (QOL). Factors potentially associated with DSP and DNP progression included disease severity, treatment, demographics, and co-morbidities. Adjusted odds ratios were calculated for follow-up neuropathy outcomes.
Of 254 participants, 21.3% were women, 57.5% were non-white. Mean baseline age was 43.5 years. Polyneuropathy prevalence increased from 25.7% to 43.7%. Of 173 participants initially pain-free, 42 (24.3%) had incident neuropathic pain. Baseline risk factors for incident pain included unemployment (OR [95% CI], 5.86 [1.97, 17.4]) and higher baseline body mass index (BMI) (1.78 [1.03, 3.19] per 10-units). Participants with neuropathic pain at follow-up had significantly worse QOL and greater dependence in activities of daily living than those who remained pain-free.
HIV DSP and neuropathic pain increased in prevalence and severity over 12 years despite high rates of viral suppression. The high burden of neuropathy included disability and poor life quality. However, substantial numbers remained pain-free despite clear evidence of neuropathy on exam. Protective factors included being employed and having a lower BMI. Implications for clinical practice include promotion of lifestyle changes affecting reversible risk factors.
在病毒得到抑制的 HIV 感染者中,远端感觉性多发性神经病(DSP)和神经性疼痛是重要的临床关注点。我们确定了这些情况的演变方式、影响其演变的因素以及它们的临床影响。
在六个研究中心招募了进行日常活动、居住在社区的 HIV 血清阳性个体。在基线和 12 年后进行临床评估,以确定神经病体征和远端神经性疼痛(DNP)。其他评估测量了日常生活活动和生活质量(QOL)。与 DSP 和 DNP 进展相关的潜在因素包括疾病严重程度、治疗、人口统计学和合并症。针对随访神经病结局计算了调整后的优势比。
在 254 名参与者中,21.3%为女性,57.5%为非白人。基线时的平均年龄为 43.5 岁。多发性神经病的患病率从 25.7%增加到 43.7%。在 173 名最初无痛的参与者中,有 42 名(24.3%)发生了神经性疼痛。发生疼痛的基线危险因素包括失业(比值比 [95%CI],5.86 [1.97,17.4])和较高的基线体重指数(BMI)(每增加 10 个单位,1.78 [1.03,3.19])。在随访时有神经性疼痛的参与者的生活质量明显更差,日常生活活动的依赖性也更大,而那些仍然无痛的参与者则没有。
尽管病毒抑制率很高,但在 12 年内,HIV DSP 和神经性疼痛的患病率和严重程度都有所增加。神经病变的高负担包括残疾和生活质量差。然而,尽管在检查中明确存在神经病,但仍有大量患者保持无痛。保护因素包括就业和较低的 BMI。对临床实践的影响包括促进影响可逆转危险因素的生活方式改变。